Trial Outcomes & Findings for ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED) (NCT NCT00535730)

NCT ID: NCT00535730

Last Updated: 2017-04-12

Results Overview

GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly. \*gpELISA = glycoprotein enzyme-linked immunosorbent assay

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

473 participants

Primary outcome timeframe

4 weeks postvaccination

Results posted on

2017-04-12

Participant Flow

Phase III First subject enrolled on 18-Jun-2007. Last subject enrolled on 05-Dec-2007. The last subject's last visit was 11-Feb-2008. The study was conducted at 18 study centers throughout Canada, Australia, and Europe.

Participant milestones

Participant milestones
Measure
Nonconcomitant Group
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Overall Study
STARTED
236
237
Overall Study
COMPLETED
234
230
Overall Study
NOT COMPLETED
2
7

Reasons for withdrawal

Reasons for withdrawal
Measure
Nonconcomitant Group
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Overall Study
Adverse Event
1
1
Overall Study
Lost to Follow-up
0
1
Overall Study
Physician Decision
0
1
Overall Study
Protocol Violation
1
0
Overall Study
Withdrawal by Subject
0
4

Baseline Characteristics

ZOSTAVAX™ Administered Concomitantly With PNEUMOVAX™ 23 (V211-012)(COMPLETED)

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Nonconcomitant Group
n=236 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=235 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Total
n=471 Participants
Total of all reporting groups
Age, Continuous
66.0 years
STANDARD_DEVIATION 5.6 • n=5 Participants
66.3 years
STANDARD_DEVIATION 5.6 • n=7 Participants
66.2 years
STANDARD_DEVIATION 5.6 • n=5 Participants
Sex: Female, Male
Female
135 Participants
n=5 Participants
138 Participants
n=7 Participants
273 Participants
n=5 Participants
Sex: Female, Male
Male
101 Participants
n=5 Participants
97 Participants
n=7 Participants
198 Participants
n=5 Participants
Race/Ethnicity, Customized
Asian
1 participants
n=5 Participants
1 participants
n=7 Participants
2 participants
n=5 Participants
Race/Ethnicity, Customized
Black or African American
0 participants
n=5 Participants
1 participants
n=7 Participants
1 participants
n=5 Participants
Race/Ethnicity, Customized
White
235 participants
n=5 Participants
233 participants
n=7 Participants
468 participants
n=5 Participants

PRIMARY outcome

Timeframe: 4 weeks postvaccination

Population: Analysis was per protocol. The following protocol violations resulted in exclusion of subjects from analysis: receipt of prohibited medications; vaccine temperature compromised prior to administration; excluded medical condition; samples collected outside of Statistical Analysis Plan specified time window; exposure to herpes zoster (HZ) or VZV.

GMT of the VZV antibody responses at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly. \*gpELISA = glycoprotein enzyme-linked immunosorbent assay

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=225 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=217 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Geometric Mean Titer (GMT) of Varicella-zoster Virus (VZV) Antibody Responses at 4 Weeks Postvaccination
448.5 gpELISA units*/mL
Interval 400.3 to 502.4
371.6 gpELISA units*/mL
Interval 328.7 to 420.0

PRIMARY outcome

Timeframe: Four weeks postvaccination

Population: Analysis was per protocol. The following protocol violations resulted in exclusion of subjects from analysis: receipt of prohibited medications; vaccine temperature compromised prior to administration; excluded medical condition; samples collected outside of Statistical Analysis Plan specified time window; exposure to herpes zoster (HZ) or VZV.

GMFR of the VZV antibody response from prevaccination to Week 4 postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23. gpELISA = glycoprotein enzyme-linked immunosorbent assay.

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=217 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Geometric Mean Fold Rise (GMFR) of the Varicella-zoster Virus (VZV) Antibody Responses From Day 1 to 4 Weeks Postvaccination.
1.9 gpELISA units/mL
Interval 1.7 to 2.1

PRIMARY outcome

Timeframe: Four weeks postvaccination

Population: Analysis was per protocol. The following protocol violations resulted in exclusion of subjects from analysis: prior receipt of a pneumococcal vaccine; receipt of prohibited medications; vaccine temperature compromised prior to administration; excluded medical condition; samples collected outside of Statistical Analysis Plan specified time window.

GMT of the PnPs serotype 3 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=228 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=219 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 3 Antibody Response at 4 Weeks Postvaccination.
1.2 micrograms/mL
Interval 1.1 to 1.4
1.1 micrograms/mL
Interval 1.0 to 1.2

PRIMARY outcome

Timeframe: Four weeks postvaccination

Population: Analysis was per protocol. The following protocol violations resulted in exclusion of subjects from analysis: prior receipt of a pneumococcal vaccine; receipt of prohibited medications; vaccine temperature compromised prior to administration; excluded medical condition; samples collected outside of Statistical Analysis Plan specified time window.

GMT of the PnPs serotype 14 antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=228 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=219 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 14 Antibody Response at 4 Weeks Postvaccination.
26.5 micrograms/mL
Interval 22.9 to 30.8
25.7 micrograms/mL
Interval 21.8 to 30.3

PRIMARY outcome

Timeframe: Four weeks postvaccination

Population: Analysis was per protocol. The following protocol violations resulted in exclusion of subjects from analysis: prior receipt of a pneumococcal vaccine; receipt of prohibited medications; vaccine temperature compromised prior to administration; excluded medical condition; samples collected outside of Statistical Analysis Plan specified time window.

GMT of the PnPs serotype 19A antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=228 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=219 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 19A Antibody Response at 4 Weeks Postvaccination.
10.5 micrograms/mL
Interval 8.7 to 12.6
10.5 micrograms/mL
Interval 8.7 to 12.7

PRIMARY outcome

Timeframe: Four weeks postvaccination

Population: Analysis was per protocol. The following protocol violations resulted in exclusion of subjects from analysis: prior receipt of a pneumococcal vaccine; receipt of prohibited medications; vaccine temperature compromised prior to administration; excluded medical condition; samples collected outside of Statistical Analysis Plan specified time window.

GMT of the PnPs serotype 22F antibody response at 4 weeks postvaccination in subjects who receive ZOSTAVAX™ concomitantly with PNEUMOVAX™ 23 and those who receive ZOSTAVAX™ and PNEUMOVAX™ 23 nonconcomitantly.

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=228 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=219 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Geometric Mean Titer (GMT) of the Pneumococcal Polysaccharide (PnPs) Serotype 22F Antibody Response at 4 Weeks Postvaccination.
2.8 micrograms/mL
Interval 2.3 to 3.3
2.5 micrograms/mL
Interval 2.1 to 3.0

SECONDARY outcome

Timeframe: Eight weeks postvaccination

Population: All subjects who received at least one vaccination

All adverse events were analyzed including serious adverse events; injection-site adverse events; Vaccination Report Card prompted systemic adverse events, including varicella-like rashes or herpes zoster-like rashes; all other systemic adverse events.

Outcome measures

Outcome measures
Measure
Nonconcomitant Group
n=236 Participants
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Concomitant Group
n=235 Participants
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
Injection site AEs
141 Participants
136 Participants
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
Systemic AEs
74 Participants
70 Participants
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
Serious AEs
4 Participants
2 Participants
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
Varicella-like Rash
3 Participants
2 Participants
Safety and Tolerability of Both Vaccines When Administered Concomitantly.
Zoster-like Rash
1 Participants
1 Participants

Adverse Events

Concomitant Group

Serious events: 2 serious events
Other events: 143 other events
Deaths: 0 deaths

Nonconcomitant Group

Serious events: 4 serious events
Other events: 154 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Concomitant Group
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Nonconcomitant Group
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Skin and subcutaneous tissue disorders
Dermatitis contact
0.43%
1/235
0.00%
0/236
Ear and labyrinth disorders
Vertigo
0.43%
1/235
0.00%
0/236
Respiratory, thoracic and mediastinal disorders
Chronic obstructive pulmonary disease
0.00%
0/235
0.42%
1/236
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
Non-Hodgkin's Lymphoma
0.00%
0/235
0.42%
1/236
Vascular disorders
Haematoma
0.00%
0/235
0.42%
1/236
Infections and infestations
Diverticulitis
0.00%
0/235
0.42%
1/236
Nervous system disorders
Global amnesia
0.00%
0/235
0.42%
1/236

Other adverse events

Other adverse events
Measure
Concomitant Group
Subjects were administered ZOSTAVAX™ subcutaneously concomitantly with PNEUMOVAX™ 23 intramuscularly at separate injection sites at Day 1
Nonconcomitant Group
Subjects were administered PNEUMOVAX™ 23 intramuscularly on Day 1 followed by ZOSTAVAX™ subcutaneously on Week 4
Gastrointestinal disorders
Nausea
0.85%
2/235
1.3%
3/236
Gastrointestinal disorders
Stomach discomfort
1.3%
3/235
0.00%
0/236
Gastrointestinal disorders
Vomiting
0.00%
0/235
1.3%
3/236
General disorders
Fatigue
0.43%
1/235
1.3%
3/236
General disorders
Malaise
1.3%
3/235
0.00%
0/236
General disorders
Pyrexia
2.1%
5/235
0.42%
1/236
Infections and infestations
Nasopharyngitis
3.8%
9/235
2.1%
5/236
Infections and infestations
Upper respiratory tract infection
2.1%
5/235
0.42%
1/236
Infections and infestations
Urinary tract infection
1.3%
3/235
1.7%
4/236
Musculoskeletal and connective tissue disorders
Arthralgia
0.43%
1/235
1.3%
3/236
Musculoskeletal and connective tissue disorders
Back pain
1.3%
3/235
2.1%
5/236
Musculoskeletal and connective tissue disorders
Musculoskeletal pain
0.43%
1/235
1.3%
3/236
Musculoskeletal and connective tissue disorders
Myalgia
1.7%
4/235
1.7%
4/236
Musculoskeletal and connective tissue disorders
Pain in extremity
0.85%
2/235
1.7%
4/236
Nervous system disorders
Headache
5.5%
13/235
1.7%
4/236
Respiratory, thoracic and mediastinal disorders
Cough
1.3%
3/235
0.00%
0/236
Respiratory, thoracic and mediastinal disorders
Pharyngolaryngeal pain
2.1%
5/235
1.7%
4/236
Skin and subcutaneous tissue disorders
Erythema
1.3%
3/235
1.3%
3/236
Skin and subcutaneous tissue disorders
Pruritus
0.85%
2/235
1.3%
3/236
Skin and subcutaneous tissue disorders
Rash
0.43%
1/235
2.5%
6/236
Skin and subcutaneous tissue disorders
Rash Vesicular
1.3%
3/235
1.7%
4/236
General disorders
Erythema (ZOSTAVAX™ injection site)
30.6%
72/235
29.7%
70/236
General disorders
Erythema (PNEUMOVAX™ 23 injection site)
19.6%
46/235
12.7%
30/236
General disorders
Erythema (Placebo injection site)
0.43%
1/235
3.0%
7/236
General disorders
Induration (ZOSTAVAX™ injection site)
0.85%
2/235
1.3%
3/236
General disorders
Pain (ZOSTAVAX™ injection site)
31.5%
74/235
28.8%
68/236
General disorders
Pain (PNEUMOVAX™ 23 injection site)
40.4%
95/235
34.7%
82/236
General disorders
Pain (Placebo injection site)
3.4%
8/235
8.9%
21/236
General disorders
Pruritus (ZOSTAVAX™ injection site)
4.7%
11/235
3.4%
8/236
General disorders
Swelling (ZOSTAVAX™ injection site)
28.5%
67/235
26.7%
63/236
General disorders
Swelling (PNEUMOVAX™ 23 injection site)
20.9%
49/235
12.7%
30/236
General disorders
Swelling (Placebo injection site)
1.3%
3/235
2.1%
5/236

Additional Information

Senior Vice President, Global Clinical Development

Merck Sharp & Dohme Corp

Phone: 1-800-672-6372

Results disclosure agreements

  • Principal investigator is a sponsor employee Merck agreements may vary with individual investigators, but will not prohibit any investigator from publishing. Merck supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
  • Publication restrictions are in place

Restriction type: OTHER